128 related articles for article (PubMed ID: 38417873)
1. Successful treatment of isolated central nervous system recurrence of primary testicular lymphoma by autologous stem cell transplantation using a conditioning regimen of thiotepa and busulfan.
Tanaka Y; Sakai T; Tsunemine H; Ito T; Arima N
J Clin Exp Hematop; 2024 Mar; 64(1):32-36. PubMed ID: 38417873
[TBL] [Abstract][Full Text] [Related]
2. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant.
Oh DH; Chua N; Street L; Stewart DA
Leuk Lymphoma; 2016; 57(1):28-33. PubMed ID: 25747968
[TBL] [Abstract][Full Text] [Related]
5. Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.
Takahashi M; Sumitani R; Hori T; Murai J; Kawata S; Oura M; Sogabe K; Harada T; Fujii S; Miki H; Kagawa K; Abe M; Nakamura S
J Med Invest; 2021; 68(1.2):196-201. PubMed ID: 33994471
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
[TBL] [Abstract][Full Text] [Related]
7. High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement.
Qualls D; Sullivan A; Li S; Brunner AM; Collier K; Hochberg E; Armand P; Batchelor TT; Chen YB; DeFilipp Z
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):884-888. PubMed ID: 28870642
[TBL] [Abstract][Full Text] [Related]
8. Secondary failure of platelet recovery in patients treated with high-dose thiotepa and busulfan followed by autologous stem cell transplantation.
Wada F; Nishikori M; Hishizawa M; Watanabe M; Aiba A; Kitano T; Shimazu Y; Shindo T; Kondo T; Takaori-Kondo A
Int J Hematol; 2020 Nov; 112(5):609-613. PubMed ID: 32980953
[TBL] [Abstract][Full Text] [Related]
9. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.
Hyung J; Hong JY; Yoon DH; Kim S; Park JS; Park CS; Lee SW; Kim JH; Ryu JS; Huh J; Suh C
Ann Hematol; 2019 Jul; 98(7):1657-1664. PubMed ID: 30989325
[TBL] [Abstract][Full Text] [Related]
10. Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma.
Delphine L; Pierre-Edouard D; Bruno R; Bérengère G; Magalie J; Patrick V; Jean-Pierre M; Pierre M
Med Sci (Basel); 2023 Jan; 11(1):. PubMed ID: 36810481
[TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
12. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM; Cwynarski K; Pulczynski E; Fox CP; Schorb E; La Rosée P; Binder M; Fabbri A; Torri V; Minacapelli E; Falautano M; Ilariucci F; Ambrosetti A; Roth A; Hemmaway C; Johnson P; Linton KM; Pukrop T; Sønderskov Gørløv J; Balzarotti M; Hess G; Keller U; Stilgenbauer S; Panse J; Tucci A; Orsucci L; Pisani F; Levis A; Krause SW; Schmoll HJ; Hertenstein B; Rummel M; Smith J; Pfreundschuh M; Cabras G; Angrilli F; Ponzoni M; Deckert M; Politi LS; Finke J; Reni M; Cavalli F; Zucca E; Illerhaus G;
Lancet Haematol; 2017 Nov; 4(11):e510-e523. PubMed ID: 29054815
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
14. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
15. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen.
Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199
[TBL] [Abstract][Full Text] [Related]
16. Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Puckrin R; Chua N; Shafey M; Stewart DA
Leuk Lymphoma; 2022 Oct; 63(10):2444-2452. PubMed ID: 35459424
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
18. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide.
Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM
Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937
[TBL] [Abstract][Full Text] [Related]
20. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
Schenone L; Houillier C; Tanguy ML; Choquet S; Agbetiafa K; Ghesquières H; Damaj G; Schmitt A; Bouabdallah K; Ahle G; Gressin R; Cornillon J; Houot R; Marolleau JP; Fornecker LM; Chinot O; Peyrade F; Bouabdallah R; Moluçon-Chabrot C; Gyan E; Chauchet A; Casasnovas O; Oberic L; Delwail V; Abraham J; Roland V; Waultier-Rascalou A; Willems L; Morschhauser F; Fabbro M; Ursu R; Thieblemont C; Jardin F; Tempescul A; Malaise D; Touitou V; Nichelli L; Le Garff-Tavernier M; Plessier A; Bourget P; Bonmati C; Wantz-Mézières S; Giordan Q; Dorvaux V; Charron C; Jabeur W; Hoang-Xuan K; Taillandier L; Soussain C;
Bone Marrow Transplant; 2022 Jun; 57(6):966-974. PubMed ID: 35422077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
